Floatz logo

17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL

Mixed Anxiety And Depressive Disorder

Massachusetts General HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Mixed Anxiety And Depressive Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Massachusetts General Hospital
Phase 4BB
TENOFOVIR DISOPROXIL FUMARATE
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
(±)-FTC
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
Gardasil 9 Vaccine
Eunice Dube
Phase 4BB
Azithromycin
University of California, San Francisco
Phase 4BB

View all 19 →

Same molecule, other indications

17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL is also rated in:

major depressive disorderDormant
BBB
Indicative ·
72 / 100
View asset →
substance abuseDormant
BB
Indicative ·
69 / 100
View asset →
schizoaffective bipolar disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →